…Decision Support (e.g. evidence-based guidelines, continuing professional development programs) and Clinical Information Systems (e.g. recall reminder systems and registries for planning care) (Adams 2007). Many of these domains are addressed…

…137 848 www.quitnow.gov.au/; NZ, 0800 778 778). Ex-smokers who attend for follow-up are more likely to be successful in the long term. Support is most needed in the first few…

…rebates for organising or participating in case conferences. Further information about item numbers is available at http://www.health.gov.au/mbsprimarycareitems The multidisciplinary care plan may include a component of self-management with appropriate support….

…feedback on step-count throughout the intervention), improved steps per day (median (IQR) 1153 (791-3199) steps per day) compared with usual care in a systematic review and meta-analysis (Reilly 2023) [evidence…

…therapy (CBT). In contrast, for physical outcomes, only mind-body interventions (e.g. mindfulness-based therapy, yoga, and relaxation) revealed a statistically significant effect. These findings favour psychosocial intervention as a tool in…

…time to first exacerbation (277.9 days versus 249.8 days; p= 0.029). Higher pneumonia rates were noted with budesonide/formoterol 320/9 mg 6.4% compared with 2.7% for formoterol alone (Sharafkhaneh 2013). A…

…40.4%, and 56.8% versus 77.3% respectively (p<0.001). At four years the median survival was significantly shorter for those with frailty (adjusted HR 1.66; 95% CI 1.54 to 1.80). These data…

…during the previous 12 months. The pharmacological treatments most frequently tried were nicotine replacement therapy (205, 57.4%) and varenicline (110, 30.8%). However, non-evidence-based treatments such as hypnotherapy (62, 17%) and…

…disorders (25.2% for patients with COPD vs 13.1% for comparators), osteoporosis/hip fractures (17.4% vs 9.9%), diabetes (15.6% vs 10.5%), peripheral arterial disease (13.5% vs 4.9%), and heart failure (13.3% vs…

…1.10-1.15), and mortality (HR 1.19, 95% CI 1.14-1.25) (Shuai 2021) [evidence level I]. Based on the available evidence, theophylline cannot be recommended for patients with COPD. O2.2 Phosphodiesterase type-4 inhibitors…